EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

Jena Shaw Tronieri, Robert F Kushner iD, Caroline M Apovian iD, Angela Fitch iD, Christopher Still, Thomas A Wadden iD

Obesity · 2026-05 · 34 (5) · 1010-1019

DOI: 10.1002/oby.70183 ↗

At a glance

Journal article in Obesity, published online on 2026-03-31. Written by Jena Shaw Tronieri and 5 co-authors. Institution: Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsy…. Major MEDLINE topics: Naltrexone, Bupropion, Obesity, Depression. 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Currax Pharmaceuticals, LLC.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

The present study examined the safety and efficacy of the fixed‐dose, extended‐release combination of naltrexone and bupropion (NB‐ER) in individuals with overweight/obesity and mild to moderate symptoms of depression.

Methods

Data were pooled from four double‐blind, placebo‐controlled trials. Participants with baseline Inventory of Depressive Symptomatology—Self‐Report scores ≥ 14 suggestive of mild or greater depressive symptoms were included ( N = 511). Primary outcomes were 56‐week percent weight loss and changes in depression, as well as safety data for psychiatric adverse events (PAEs), depressive symptom increases, and suicidal ideation. Multiple imputation was applied, and outcomes were compared in the intention‐to‐treat population.

Results

In participants with symptoms of depression, 56‐week weight loss was significantly greater with NB‐ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003). Participants experienced clinically meaningful improvements in depression of −7.1 ± 0.4 with NB‐ER and −6.7 ± 0.5 with placebo, with no significant differences between the groups. NB‐ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB‐ER vs. 22.1% placebo), depressive symptom increases (9.5% NB‐ER vs. 8.8% placebo), or suicidal ideation (1.8% NB‐ER vs. 2.0% placebo).

Conclusions

NB‐ER appears to be both safe and effective for weight loss when offered to patients with mild to moderate symptoms of depression.

Subjects

MeSH terms (MEDLINE)

NaltrexoneBupropionObesityDepressionOverweightHumansFemaleMaleWeight LossDouble-Blind MethodMiddle AgedAdultSuicidal IdeationTreatment OutcomeDrug Combinations

Author keywords

depressionpharmacologic therapyweight management

Substances

NaltrexoneBupropionDrug Combinations

Authors and institutions

  • Department of Psychiatry, Center for Weight and Eating Disorders, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Brigham and Women's Hospital Center for Weight Management and Wellness, Boston, Massachusetts, USA.
  • Knownwell, Needham, Massachusetts, USA.
  • Geisinger Commonwealth School of Medicine, Danville, Pennsylvania, USA.

ORCID profiles: Robert F Kushner, Caroline M Apovian, Angela Fitch, Thomas A Wadden

Funding

  • Currax Pharmaceuticals, LLC

Cite

APA

Tronieri, J. S., Kushner, R. F., Apovian, C. M., Fitch, A., Still, C., & Wadden, T. A. (2026). Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity, 34(5), 1010-1019. https://doi.org/10.1002/oby.70183

Vancouver

Tronieri JS, Kushner RF, Apovian CM, Fitch A, Still C, Wadden TA. Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis. Obesity. 2026;34(5):1010-1019. doi:10.1002/oby.70183

BibTeX
@article{Tronieri2026,
  author = {Tronieri, Jena Shaw and Kushner, Robert F and Apovian, Caroline M and Fitch, Angela and Still, Christopher and Wadden, Thomas A},
  title = {Use of Naltrexone–Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {1010--1019},
  doi = {10.1002/oby.70183}
}
Start for free →